<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426009</url>
  </required_header>
  <id_info>
    <org_study_id>EP-101-03</org_study_id>
    <nct_id>NCT01426009</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine steady-state efficacy and dose response profile and
      to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing
      using an investigational high efficiency nebulizer (eFlow®) compared with placebo and two
      active comparators in patients with moderate to severe Chronic Obstructive Pulmonary Disease
      (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period,
      incomplete block design cross-over study using EP-101(SUN101) and open-label active controls
      (tiotropium bromide and ipratropium bromide). The study population will consist of subjects
      of 40-75 years of age with moderate to severe COPD. Approximately 133 subjects diagnosed with
      moderate to severe COPD will be enrolled in order to achieve minimum 105 subjects completing
      the study.

      Following a run-in phase, each subject will be randomly assigned to one of 7 treatment
      sequences,(96 sequences when order of administration is considered), with each sequence
      comprised of four 7-day Treatment Periods. There will be a washout period of 7 days between
      each Treatment Period. Study visits will be conducted on Days 1 and 7 of each Treatment
      Period, with an overnight stay required in the clinic during these visits. A Final Study
      Visit will be conducted 7 days following the last study treatment.

      During each Treatment Period, study treatments will be administered once daily (QD), except
      for ipratropium inhalation solution, which will be administered three times daily (TID).
      EP-101 (SUN101)active and placebo treatments will be administered using an investigational
      high-efficiency eFlow® nebulizer. Tiotropium bromide (Spiriva®) will be administered in an
      open-label manner via Handihaler® dry-powder inhaler (DPI). Ipratropium bromide inhalation
      solution will be administered in an open-label manner via general purpose nebulizer.

      This study was previously posted by Elevation Pharmaceuticals, Inc. On September 5, 2012,
      Elevation was acquired by merger with Sunovion Pharmaceuticals Inc. (&quot;Sunovion&quot;), which
      resulted in Elevation becoming a direct wholly-owned subsidiary of Sunovion. In conjunction
      with this acquisition, the name of Elevation has been changed to Sunovion Respiratory
      Development Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours post dose for Day 1 and Day 7 within each Treatment Period. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period. Change from baseline was calculated as the trough FEV1 value minus the baseline for Day 1 and Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized FEV1 AUC(0-12hr and 12-24hr) on Day 1 and Day 7 was calculated using the trapezoidal rule from the changes in FEV1 at Day 1 and Day 7, respectively, from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7)</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Clinically meaningful is defined as when the change from baseline (mean of the two pre-dose values at Day 1) in 24 hour trough FEV1 on a SUN-101 treatment is more than 100 mL compared to the mean change in trough FEV1 from all subjects on the placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. Vital signs were performed during the screening period to confirm study eligibility and at the final study visit. ECGs were performed during the screening period to confirm study eligibility. Vital signs and ECG were additionally collected within 30 minutes pre-dose; and 30 minutes, and 1, 2, 4, 6, 12 hours, and 23 hours 45 minutes post-dose within each treatment period. Clinical laboratory assessments were conducted during the screening period, at each study visit during each treatment period, and at the final study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>Day 1 through Day 7</time_frame>
    <description>Mean number of puffs of daily rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>percentage of subjects with clinically meaningful change from pre-dose in trough FEV1 on Day 1 and Day 7 Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 25 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EP-101 via nebulizer (eFlow®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium bromide via (Spiriva® Handihaler®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium bromide via (Spiriva® Handihaler®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipratropium bromide Inhalation Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo EP-101</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 50 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EP-101 via nebulizer (eFlow®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 100 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EP-101 via nebulizer (eFlow®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 200 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EP-101 via nebulizer (eFlow®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-101 via nebulizer (eFlow®) 25 ug</intervention_name>
    <description>EP-101 (25 ug ) Dose 1 administered once daily for 7 days</description>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 25 ug</arm_group_label>
    <other_name>SUN101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-101 via nebulizer (eFlow®) 50 ug</intervention_name>
    <description>EP-101 (50 ug ) administered once daily for 7 days</description>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 50 ug</arm_group_label>
    <other_name>SUN101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-101 via nebulizer (eFlow®) 100 ug</intervention_name>
    <description>EP-101 (100ug) administered once daily for 7 days</description>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 100 ug</arm_group_label>
    <other_name>SUN101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo EP-101</intervention_name>
    <description>Placebo EP-101 administered once daily for 7 days</description>
    <arm_group_label>Placebo EP-101</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide via (Spiriva® Handihaler®)</intervention_name>
    <description>Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
    <arm_group_label>Tiotropium bromide via (Spiriva® Handihaler®)</arm_group_label>
    <other_name>Tiotropium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide Inhalation Solution via Handihaler® DPI</intervention_name>
    <description>Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
    <arm_group_label>Ipratropium bromide Inhalation Solution</arm_group_label>
    <other_name>Ipratropium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP-101 via nebulizer (eFlow®) 200 ug</intervention_name>
    <description>EP-101 (200) ug administered once daily for 7 days</description>
    <arm_group_label>EP-101 via nebulizer (eFlow®) 200 ug</arm_group_label>
    <other_name>SUN101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40-75 years of age

          -  Clinical diagnosis of moderate to severe COPD

          -  Current/ex-smokers with at least 10 pack-year smoking history

          -  Post-bronchodilator FEV1 ≥ 30% and ≤ 70% predicted normal values

          -  Post-bronchodilator FEV1/FVC ratio of ≤ 0.70

          -  Post-bronchodilator improvement in FEV1 ≥ 12% and ≤ 30%, and a minimum of 100 mL

          -  Willing and able to remain at the study site for at least 24 hours at each study visit

          -  Signed written informed consent

        Exclusion Criteria:

          -  Current evidence or recent history of any clinically significant and unstable disease
             or abnormality (e.g., myocardial infarction, cardiac failure, uncontrolled
             hypertension, life-threatening arrhythmias, uncontrolled diabetes)

          -  Primary diagnosis of asthma

          -  History of malignancy within the past 5 years

          -  History of COPD exacerbation within 6 weeks of Screening

          -  Daily oxygen therapy &gt; 10 hours per day

          -  Systemic steroids use within 6 weeks of Screening

          -  Respiratory tract infection within 6 weeks of Screening

          -  History of tuberculosis, bronchiectasis

          -  History of urinary retention or bladder neck obstruction type symptoms

          -  History of glaucoma

          -  Prolonged QTc interval (&gt;460msec) or history of long QT syndrome

          -  Recent history of alcohol or drug abuse

          -  Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling
             to practice acceptable birth control methods

          -  History of hypersensitivity or intolerance to aerosol medications

          -  Participation in another investigational drug study within 30 days of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmet Tutuncu, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer / Elevation Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational SIte</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevation Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M21 8AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>April 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2018</results_first_posted>
  <disposition_first_submitted>December 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 24, 2014</disposition_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One randomized subject did not receive any study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total</title>
          <description>total subjects which includes:EP-101 via nebulizer (eFlow®), Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI , and Placebo EP-101&quot;,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1-First Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ipratropium Bromide</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2-Second Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ipratropium Bromide</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>electrive surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3-Third Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ipratropium Bromide</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4-Fourth Intervention (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EP-101 Via Nebulizer</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ipratropium Bromide</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Tiotropium Bromide</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>modified Intent to Treat population for analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Total Particiants</title>
          <description>total of all participants in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours post dose for Day 1 and Day 7 within each Treatment Period. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period. Change from baseline was calculated as the trough FEV1 value minus the baseline for Day 1 and Day 7.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent to treat analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours post dose for Day 1 and Day 7 within each Treatment Period. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period. Change from baseline was calculated as the trough FEV1 value minus the baseline for Day 1 and Day 7.</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent to treat analysis set</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough FEV1 - day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0477" spread="0.16359"/>
                    <measurement group_id="O2" value="0.1009" spread="0.13261"/>
                    <measurement group_id="O3" value="0.0648" spread="0.14239"/>
                    <measurement group_id="O4" value="0.0632" spread="0.14965"/>
                    <measurement group_id="O5" value="0.0933" spread="0.18980"/>
                    <measurement group_id="O6" value="0.0740" spread="0.144441"/>
                    <measurement group_id="O7" value="0.0301" spread="0.14394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough FEV1 - day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0478" spread="0.18965"/>
                    <measurement group_id="O2" value="0.0699" spread="0.16909"/>
                    <measurement group_id="O3" value="0.0666" spread="0.15132"/>
                    <measurement group_id="O4" value="0.0840" spread="0.13842"/>
                    <measurement group_id="O5" value="0.0292" spread="0.16507"/>
                    <measurement group_id="O6" value="0.0564" spread="0.16356"/>
                    <measurement group_id="O7" value="-0.155" spread="0.17934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response,with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence. A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0723</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0188</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0347</ci_lower_limit>
            <ci_upper_limit>0.1099</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response,with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0676</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0307</ci_lower_limit>
            <ci_upper_limit>0.1046</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0188</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0644</ci_lower_limit>
            <ci_upper_limit>0.1398</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1299</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0918</ci_lower_limit>
            <ci_upper_limit>00.1681</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>0.0200</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0446</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0186</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0073</ci_lower_limit>
            <ci_upper_limit>0.0820</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 7 analysis</non_inferiority_desc>
            <p_value>0.0060</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0813</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0284</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0243</ci_lower_limit>
            <ci_upper_limit>0.1382</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 1 analysis</non_inferiority_desc>
            <p_value>0.0402</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0385</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0183</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0018</ci_lower_limit>
            <ci_upper_limit>0.0752</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 1 analysis</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0696</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0179</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0337</ci_lower_limit>
            <ci_upper_limit>0.1055</ci_upper_limit>
            <estimate_desc>Standard Error of the Mean Difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>An ANCOVA was used with change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline as a covariate and a random effect for subject nested within sequence.A sample size of 30 subjects per comparison(133 total with dropouts)provides 90% power to detect a 0.12L difference in mean change trough FEV1 between active and placebo at an alpha of 0.05 using a 2-tailed t-test and assuming a within-subject standard deviation for change in trough FEV1 of 0.2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Day 1 analysis</non_inferiority_desc>
            <p_value>0.0074</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>0.0501</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0180</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0140</ci_lower_limit>
            <ci_upper_limit>0.0861</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized FEV1 AUC(0-12hr and 12-24hr) on Day 1 and Day 7 was calculated using the trapezoidal rule from the changes in FEV1 at Day 1 and Day 7, respectively, from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized FEV1 AUC(0-12hr and 12-24hr) on Day 1 and Day 7 was calculated using the trapezoidal rule from the changes in FEV1 at Day 1 and Day 7, respectively, from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval.</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1001" spread="0.15704"/>
                    <measurement group_id="O2" value="0.1520" spread="0.13646"/>
                    <measurement group_id="O3" value="0.1414" spread="0.11045"/>
                    <measurement group_id="O4" value="0.1720" spread="0.12644"/>
                    <measurement group_id="O5" value="0.1990" spread="0.13740"/>
                    <measurement group_id="O6" value="0.1213" spread="0.12548"/>
                    <measurement group_id="O7" value="0.0130" spread="0.11486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 12-24 on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0039" spread="0.17104"/>
                    <measurement group_id="O2" value="0.0681" spread="0.12835"/>
                    <measurement group_id="O3" value="0.0413" spread="0.14032"/>
                    <measurement group_id="O4" value="0.0645" spread="0.13275"/>
                    <measurement group_id="O5" value="0.0987" spread="0.16958"/>
                    <measurement group_id="O6" value="0.0499" spread="0.14532"/>
                    <measurement group_id="O7" value="-0.0245" spread="0.12151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24 on Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0525" spread="0.15495"/>
                    <measurement group_id="O2" value="0.1107" spread="0.12207"/>
                    <measurement group_id="O3" value="0.0919" spread="0.11554"/>
                    <measurement group_id="O4" value="0.1194" spread="0.11905"/>
                    <measurement group_id="O5" value="0.1496" spread="0.14425"/>
                    <measurement group_id="O6" value="0.0872" spread="0.12638"/>
                    <measurement group_id="O7" value="-0.0073" spread="0.11377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 on Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1034" spread="0.19035"/>
                    <measurement group_id="O2" value="0.1411" spread="0.16343"/>
                    <measurement group_id="O3" value="0.1329" spread="0.13416"/>
                    <measurement group_id="O4" value="0.1438" spread="0.14833"/>
                    <measurement group_id="O5" value="0.1603" spread="0.16420"/>
                    <measurement group_id="O6" value="0.1256" spread="0.15197"/>
                    <measurement group_id="O7" value="-0.0098" spread="0.15537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 12-24 on Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0112" spread="0.18136"/>
                    <measurement group_id="O2" value="0.0540" spread="0.16633"/>
                    <measurement group_id="O3" value="0.0278" spread="0.15187"/>
                    <measurement group_id="O4" value="0.0614" spread="0.13450"/>
                    <measurement group_id="O5" value="0.0357" spread="0.17382"/>
                    <measurement group_id="O6" value="0.0283" spread="0.15596"/>
                    <measurement group_id="O7" value="0.0698" spread="0.16584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24 on Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0579" spread="0.17822"/>
                    <measurement group_id="O2" value="0.0980" spread="0.15651"/>
                    <measurement group_id="O3" value="0.0812" spread="0.13293"/>
                    <measurement group_id="O4" value="0.1030" spread="0.13162"/>
                    <measurement group_id="O5" value="0.1009" spread="0.15882"/>
                    <measurement group_id="O6" value="0.0776" spread="0.14702"/>
                    <measurement group_id="O7" value="-0.0395" spread="0.15415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ACU 0-24 on Day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0767</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0505</ci_lower_limit>
            <ci_upper_limit>0.1028</ci_upper_limit>
            <estimate_desc>standard error of the mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ACU 0-24 Day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1220</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0127</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0965</ci_lower_limit>
            <ci_upper_limit>0.1475</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 Day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1222</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0128</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0965</ci_lower_limit>
            <ci_upper_limit>0.1479</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1625</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1362</ci_lower_limit>
            <ci_upper_limit>0.1888</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1690</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0128</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1434</ci_lower_limit>
            <ci_upper_limit>0.1946</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0189</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0716</ci_lower_limit>
            <ci_upper_limit>0.1473</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 on Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0812</ci_lower_limit>
            <ci_upper_limit>0.1379</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC0-24 on Day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1271</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0993</ci_lower_limit>
            <ci_upper_limit>0.1548</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1450</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0140</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1169</ci_lower_limit>
            <ci_upper_limit>0.1730</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1688</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1403</ci_lower_limit>
            <ci_upper_limit>0.1972</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1396</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0139</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1117</ci_lower_limit>
            <ci_upper_limit>0.1730</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0194</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0795</ci_lower_limit>
            <ci_upper_limit>0.1972</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0776</ci_lower_limit>
            <ci_upper_limit>0.1301</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1468</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0128</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1212</ci_lower_limit>
            <ci_upper_limit>0.1724</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1579</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0128</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1322</ci_lower_limit>
            <ci_upper_limit>0.1837</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1919</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0132</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1655</ci_lower_limit>
            <ci_upper_limit>0.2184</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1994</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0128</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1738</ci_lower_limit>
            <ci_upper_limit>0.2251</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1248</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0188</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0872</ci_lower_limit>
            <ci_upper_limit>0.1625</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>standard error of the Mean difference</method_desc>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1279</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0154</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0970</ci_lower_limit>
            <ci_upper_limit>0.1587</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1454</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0151</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1151</ci_lower_limit>
            <ci_upper_limit>0.1756</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1699</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0152</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1393</ci_lower_limit>
            <ci_upper_limit>0.2004</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1814</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0155</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1503</ci_lower_limit>
            <ci_upper_limit>0.2125</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1697</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0152</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1393</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 0-12 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1384</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0216</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0951</ci_lower_limit>
            <ci_upper_limit>0.1817</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0471</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0157</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0155</ci_lower_limit>
            <ci_upper_limit>0.0786</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0918</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0154</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0611</ci_lower_limit>
            <ci_upper_limit>0.1226</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0829</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0155</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0519</ci_lower_limit>
            <ci_upper_limit>0.1139</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 o day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1299</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0158</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0982</ci_lower_limit>
            <ci_upper_limit>0.1617</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1369</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0154</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1061</ci_lower_limit>
            <ci_upper_limit>0.1678</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0934</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0490</ci_lower_limit>
            <ci_upper_limit>0.1377</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0879</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0153</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0573</ci_lower_limit>
            <ci_upper_limit>0.1186</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0150</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0788</ci_lower_limit>
            <ci_upper_limit>0.1388</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1175</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0151</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0872</ci_lower_limit>
            <ci_upper_limit>0.1478</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1532</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0153</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1226</ci_lower_limit>
            <ci_upper_limit>0.1838</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.1048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0150</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0747</ci_lower_limit>
            <ci_upper_limit>0.1350</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>AUC 12-24 on day 7</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference (SE)</param_type>
            <param_value>0.0993</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0202</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0589</ci_lower_limit>
            <ci_upper_limit>0.1398</ci_upper_limit>
            <estimate_desc>standard error of the Mean difference</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7)</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7)</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 trough FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.469" spread="0.5049"/>
                    <measurement group_id="O2" value="1.498" spread="0.4857"/>
                    <measurement group_id="O3" value="1.443" spread="0.4431"/>
                    <measurement group_id="O4" value="1.455" spread="0.4355"/>
                    <measurement group_id="O5" value="1.601" spread="0.4665"/>
                    <measurement group_id="O6" value="1.434" spread="0.4774"/>
                    <measurement group_id="O7" value="1.356" spread="0.4471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.482" spread="0.4993"/>
                    <measurement group_id="O2" value="1.496" spread="0.4694"/>
                    <measurement group_id="O3" value="1.462" spread="0.4300"/>
                    <measurement group_id="O4" value="1.453" spread="0.4476"/>
                    <measurement group_id="O5" value="1.594" spread="0.4943"/>
                    <measurement group_id="O6" value="1.475" spread="0.4556"/>
                    <measurement group_id="O7" value="1.348" spread="0.4465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</title>
        <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Clinically meaningful is defined as when the change from baseline (mean of the two pre-dose values at Day 1) in 24 hour trough FEV1 on a SUN-101 treatment is more than 100 mL compared to the mean change in trough FEV1 from all subjects on the placebo treatment.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</title>
          <description>Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Clinically meaningful is defined as when the change from baseline (mean of the two pre-dose values at Day 1) in 24 hour trough FEV1 on a SUN-101 treatment is more than 100 mL compared to the mean change in trough FEV1 from all subjects on the placebo treatment.</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests</title>
        <description>AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. Vital signs were performed during the screening period to confirm study eligibility and at the final study visit. ECGs were performed during the screening period to confirm study eligibility. Vital signs and ECG were additionally collected within 30 minutes pre-dose; and 30 minutes, and 1, 2, 4, 6, 12 hours, and 23 hours 45 minutes post-dose within each treatment period. Clinical laboratory assessments were conducted during the screening period, at each study visit during each treatment period, and at the final study visit.</description>
        <time_frame>Day 1 through Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication were included in the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests</title>
          <description>AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. Vital signs were performed during the screening period to confirm study eligibility and at the final study visit. ECGs were performed during the screening period to confirm study eligibility. Vital signs and ECG were additionally collected within 30 minutes pre-dose; and 30 minutes, and 1, 2, 4, 6, 12 hours, and 23 hours 45 minutes post-dose within each treatment period. Clinical laboratory assessments were conducted during the screening period, at each study visit during each treatment period, and at the final study visit.</description>
          <population>All subjects who received at least one dose of study medication were included in the safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical signicant abnormal vital signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant abnormal ECG values Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically significant abnormal ECG values Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinicall significant abnormal lab valuesday1-day7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use</title>
        <description>Mean number of puffs of daily rescue medication</description>
        <time_frame>Day 1 through Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use</title>
          <description>Mean number of puffs of daily rescue medication</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
          <units>average daily number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="2.72"/>
                    <measurement group_id="O2" value="1.11" spread="1.89"/>
                    <measurement group_id="O3" value="1.48" spread="2.43"/>
                    <measurement group_id="O4" value="1.29" spread="2.70"/>
                    <measurement group_id="O5" value="1.42" spread="2.91"/>
                    <measurement group_id="O6" value="1.33" spread="3.01"/>
                    <measurement group_id="O7" value="1.59" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</title>
        <description>percentage of subjects with clinically meaningful change from pre-dose in trough FEV1 on Day 1 and Day 7 Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O3">
            <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O4">
            <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
            <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Ipratropium Bromide Inhalation Solution</title>
            <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
            <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7)</title>
          <description>percentage of subjects with clinically meaningful change from pre-dose in trough FEV1 on Day 1 and Day 7 Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.</description>
          <population>All subjects who received at least one dose of study medication and who had Day 1 pre-dose and Day 7 through FEV1 values were included in the modified intent-to-treat (mITT) analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="35.3"/>
                    <measurement group_id="O5" value="33.8"/>
                    <measurement group_id="O6" value="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="46.6"/>
                    <measurement group_id="O4" value="51.4"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day 1 through day 7</time_frame>
      <desc>existing conditions which worsen or events which occur during the course of the clinical trial after treatment with randomized study drug has started</desc>
      <group_list>
        <group group_id="E1">
          <title>EP-101 Via Nebulizer (eFlow®) 25 mcg</title>
          <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>EP-101 Via Nebulizer (eFlow®) 50 mcg</title>
          <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
        </group>
        <group group_id="E3">
          <title>EP-101 Via Nebulizer (eFlow®)100 mcg</title>
          <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
        </group>
        <group group_id="E4">
          <title>EP-101 Via Nebulizer (eFlow®) 200 mcg</title>
          <description>EP-101 via nebulizer (eFlow®)
EP-101 via nebulizer (eFlow®): EP-101 Dose 1 administered once daily for 7 days
EP-101 via nebulizer (eFlow®): EP-101 administered once daily for 7 days</description>
        </group>
        <group group_id="E5">
          <title>Ipratropium Bromide Inhalation Solution</title>
          <description>Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium bromide Inhalation Solution via Handihaler® DPI: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer</description>
        </group>
        <group group_id="E6">
          <title>Tiotropium Bromide Via (Spiriva® Handihaler®)</title>
          <description>Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®): Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo
Placebo : Placebo administered once daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E7" events="9" subjects_affected="7" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E3" events="15" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E4" events="14" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E7" events="14" subjects_affected="9" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the study is part of a multi-center study. The first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

